Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
CoreCard Corporation CCRD: This technology solutions and processing services company has seen the Zacks Consensus Estimate for its current year earnings increasing 7% over the last 60 days.
CoreCard Corporation price-consensus-chart | CoreCard Corporation Quote
Appian Corporation APPN: This software company has seen the Zacks Consensus Estimate for its current year earnings increasing 33.3% over the last 60 days.
Appian Corporation price-consensus-chart | Appian Corporation Quote
USANA Health Sciences, Inc. USNA: This nutritional, personal care, and skincare products company has seen the Zacks Consensus Estimate for its next year earnings increasing 12.8% over the last 60 days.
USANA Health Sciences, Inc. price-consensus-chart | USANA Health Sciences, Inc. Quote
Entrada Therapeutics, Inc. TRDA: This clinical-stage biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 64.7% over the last 60 days.
Entrada Therapeutics, Inc. price-consensus-chart | Entrada Therapeutics, Inc. Quote
NRx Pharmaceuticals, Inc. NRXP: This clinical-stage biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 46.2% over the last 60 days.
NRx Pharmaceuticals, Inc. price-consensus-chart | NRx Pharmaceuticals, Inc. Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
USANA Health Sciences, Inc. (USNA) : Free Stock Analysis Report
Appian Corporation (APPN) : Free Stock Analysis Report
NRx Pharmaceuticals, Inc. (NRXP) : Free Stock Analysis Report
Entrada Therapeutics, Inc. (TRDA) : Free Stock Analysis Report
CoreCard Corporation (CCRD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。